Search Results

You are looking at 341 - 350 of 498 items for :

  • "paclitaxel" x
  • Refine by Access: All x
Clear All
Full access

Chest Wall Leiomyosarcoma After Breast-Conservative Therapy for Early-Stage Breast Cancer in a Young Woman With Li-Fraumeni Syndrome

Eve Henry, Victor Villalobos, Lynn Million, Kristin C. Jensen, Robert West, Kristen Ganjoo, Alexandra Lebensohn, James M. Ford, and Melinda L. Telli

margins were negative. Imaging revealed no evidence of metastasis. She received adjuvant chemotherapy with 4 cycles of doxorubicin and cyclophosphamide, followed by 4 cycles of paclitaxel with concurrent trastuzumab. She underwent photon irradiation using

Full access

Treatment of Cancer-Associated Retinopathy With Rituximab

Irene Dy, Rangaswamy Chintapatla, Isabel Preeshagul, and Daniel Becker

initiated for worsening vision 13 months after diagnosis. She progressed through third-line chemotherapy and started paclitaxel 16 months after diagnosis. At that time she was able to drive during the daytime and ski. She died from disease progression 18

Full access

Small Cell Lung Cancer

Gregory P. Kalemkerian, Wallace Akerley, Paul Bogner, Hossein Borghaei, Laura QM Chow, Robert J. Downey, Leena Gandhi, Apar Kishor P. Ganti, Ramaswamy Govindan, John C. Grecula, James Hayman, Rebecca Suk Heist, Leora Horn, Thierry Jahan, Marianna Koczywas, Billy W. Loo Jr, Robert E. Merritt, Cesar A. Moran, Harvey B. Niell, Janis O’Malley, Jyoti D. Patel, Neal Ready, Charles M. Rudin, Charles C. Williams Jr, Kristina Gregory, and Miranda Hughes

, the addition of paclitaxel to either cisplatin or carboplatin plus etoposide yielded promising results in phase II trials but did not improve survival, and was associated with unacceptable toxicity in a subsequent phase III study. 72 The use of

Full access

Real Personalized Medicine

James O. Armitage, William C. Wood, and Dan L. Longo

-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study . Blood 2007 ; 109 : 1408 – 1413 . 13. Mok TS Wu YL Thongprasert S . Fefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma . N Engl J Med 2009 ; 361 : 947 – 957

Full access

NCCN Roundtable:Value-Based Decision-Making at the Bedside

Peter B. Bach, Stephen B. Edge, Linda House, Jennifer Malin, James L. Mohler, and Clifford Goodman

practices derive the bulk of their revenue from drug margins. For example, in the case of non-small cell lung cancer, regimens can range from $450 for 4 cycles of carboplatin/paclitaxel to $65,000 for 4 cycles of 3 other agents. Depending on which regimen is

Full access

Temporal Heterogeneity of Estrogen Receptor Expression in Bone-Dominant Breast Cancer: 18F-Fluoroestradiol PET Imaging Shows Return of ER Expression

Erin Currin, Lanell M. Peterson, Erin K. Schubert, Jeanne M. Link, Kenneth A. Krohn, Robert B. Livingston, David A. Mankoff, and Hannah M. Linden

, spine), treatment was switched to weekly paclitaxel and disease control was seen for 1 year, but then the tumor again progressed in bone and soft tissue, with worsening pain, increasing and diffuse bone and bone marrow involvement shown on FDG

Full access

Treatment of Metastatic Breast Cancer

William J. Gradishar

that triple-drug regimen significantly prolonged progression-free and overall survivals. Paclitaxel could be used instead of docetaxel in this triplet, and this is noted in the NCCN Guidelines for Breast Cancer. Trastuzumab in combination with eribulin

Full access

Combined Modality Therapy of Localized Gastric and Esophageal Cancers

Prajnan Das, Norio Fukami, and Jaffer A. Ajani

patients with potentially resectable gastric carcinoma . J Clin Oncol 2004 ; 22 : 2774 – 2780 . 41. Ajani JA Mansfield PF Crane CH . Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not

Full access

Novel Targets for Therapeutic Agents in Small Cell Lung Cancer

Patrick C. Ma and Ravi Salgia

Oncol Clin North Am 1995 ; 9 : 451 – 473 . 55 Rudin CM Otterson GA Mauer AM . A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer . Ann Oncol 2002 ; 13 : 539

Full access

NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022

Featured Updates to the NCCN Guidelines

Thomas W. Flaig, Philippe E. Spiess, Michael Abern, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Kevin Chan, Sam Chang, Terence Friedlander, Richard E. Greenberg, Khurshid A. Guru, Harry W. Herr, Jean Hoffman-Censits, Amar Kishan, Shilajit Kundu, Subodh M. Lele, Ronac Mamtani, Vitaly Margulis, Omar Y. Mian, Jeff Michalski, Jeffrey S. Montgomery, Lakshminarayanan Nandagopal, Lance C. Pagliaro, Mamta Parikh, Anthony Patterson, Elizabeth R. Plimack, Kamal S. Pohar, Mark A. Preston, Kyle Richards, Wade J. Sexton, Arlene O. Siefker-Radtke, Matthew Tollefson, Jonathan Tward, Jonathan L. Wright, Mary A. Dwyer, Carly J. Cassara, and Lisa A. Gurski

bladder cancer who previously received chemotherapy and subsequently experienced disease progression or metastasis. 50 An open-label, randomized, phase III trial compared pembrolizumab versus chemotherapy (paclitaxel, docetaxel, or vinflunine) in 542